Press Release: First Heart Patient Treated in Adipose Stem Cell Trial

First Heart Patient Treated in Adipose Stem Cell Trial; Cytori's Cardiovascular Stem Cell Study Initiated SAN DIEGO & MADRID, Spain -- Feb 5, 2007 - Cytori Therapeutics and Hospital Gregorio Maranon in Madrid, Spain treated the first patient in Cytori's randomized clinical trial investigating the safety and feasibility of adipose-derived stem and regenerative cells as a therapy for cardiovascular disease. The study, designated as the 'PRECISE' trial, will enroll patients suffering from chronic myocardial ischemia, a severe form of end-stage coronary artery disease, which is estimated to affect hundreds of thousands of patients in Europe and the United States. Patients in the study will receive their own adult stem and regenerative cells, thereby avoiding the risk of rejection or disease transmission that exists with donor stem cells and the controversy associated with embryonic stem cells. Once introduced into a patient's heart, the cells have shown preclinically to help the body improve blood supply that can restore circulation to the heart. "Patients with chronic heart disease today have few options making this an important milestone for the affected patients and doctors that treat them," said Marc H. Hedrick, M.D., President for Cytori Therapeutics. "This study is designed to show unequivocally whether the cells from our Celution System(TM) can be safely introduced into the heart. Our ultimate goal is to asses the clinical therapeutic effect of the cells, which were shown in preclinical studies to significantly improve heart function." Adipose Tissue: Rich Cell Source Adipose tissue, commonly known as fat, is the human body's richest known source of stem cells, as well as other cells that are believed to contribute to repair and healing, referred to as "regenerative cells." Due to its abundance and accessibility in the body, adipose tissue represents an ideal source for immediate access to a patient's own stem and regenerative cells. The Celution(TM) System For the PRECISE study, stem and regenerative cells are obtained at the bedside from the patients' own adipose tissue and made available in real-time using Cytori's Celution(TM) System. The Celution(TM) System automates and standardizes the complex process that releases stem and regenerative cells locked within adipose tissue. Adipose tissue is removed from the patient using a minor liposuction-like procedure, placed into the system and, with the touch of a button, processed. About an hour later, a prescribed dose of stem and regenerative cells are delivered to the patient. Clinical Trial Details The PRECISE study will evaluate the safety and feasibility of using adipose-derived stem and regenerative to treat 36 patients with chronic myocardial ischemia whom cannot be effectively treated by other means. The cells will be processed with the Celution(TM) System in the catheterization lab so they are available for the physician to re-inject into damaged heart muscle in about an hour using the NOGA(R) mapping and delivery system. A variety of clinical functional and imaging endpoints will be assessed in the study. The outcomes of the study will be evaluated after a six month follow-up period. The PRECISE study is being conducted at the Hospital General Universitario Gregorio (HGU G) Maranon in Madrid, Spain. Professor Francisco Fernandez-Aviles, professor of cardiovascular medicine and chief of cardiology service at HGU G Maranon, and Dr. Emerson Perin, director of the New Interventional Cardiovascular Technology and director of the Stem Cell Center at the Texas Heart Institute will serve as co-principal investigators. "Cytori's stem cell technology has the potential to become the next major advancement in cardiovascular disease care," said Dr. Aviles. "Their device is user-friendly and enables the delivery of patient's cells at the bedside without ever leaving the catheterization lab." "These cells may be optimal for targeting cardiovascular disease due to their ability to promote blood vessel growth," said Dr. Perin. "This primary mode of action demonstrated in pre-clinical studies could result in significant clinical benefit." About Cytori Therapeutics Cytori Therapeutics is developing and seeks to commercialize stem and regenerative cell therapies for cardiovascular disease, reconstructive surgery and many other serious chronic, and life threatening conditions. To provide these therapies, physicians remove a small amount of a patient's fat, also known as adipose tissue, and run it through Cytori's Celution(TM) System. This System quickly separates and concentrates stem and regenerative cells from adipose tissue so they may be quickly administered back to the patient about an hour later. This system will dramatically improve the way in which personalized cell-based therapies can be delivered to patients. www.cytoritx.com Cautionary Statement Regarding Forward-Looking Statements This press release includes forward-looking statements regarding events, trends and prospects of our business, which may affect our future operating results and financial position. Such statements are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks and uncertainties include our history of operating losses and expected continuing losses, the need for further financing, our ability to develop and commercialize regenerative cell-based therapies, our dependence on third parties, our ability to obtain, defend and enforce our intellectual property, and other risks and uncertainties described (under the heading "Risk Factors") in Cytori Therapeutics' Form 10-K annual report for the year ended December 31, 2005 and subsequent SEC filings. We assume no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made.

Suggested Articles

A COVID-19 vaccine developed by a Mass General spinoff is among the candidates emerging from partnerships between tech developers and bio researchers.

Compass' CD137 agonist cleared large tumors in mice that other I-O agents had failed to treat. It's advancing the drug into phase 1 human trials.

UPMC researchers are planning clinical trials of a COVID-19 vaccine that uses pieces of the virus' spike protein to create immunity.